Medplus rallies 31% as scrip sharply rebounds from 52-wk lows; is there more steam left?
Gross margin was impressive at 21.7%, upheld by private label share and store expansion was on track with 614 stores in H1FY23. It had a ‘buy’ rating on the counter but its target price of Rs 750 has already been hit by the company.
